Partner

Articles & Insights / Analytical Lifecycle

Connecting Analytical Development and Validation with ICH Q2 R2 and Q14

Analytical validation is most useful when it confirms a procedure developed for a clearly defined measurement need. ICH Q14 and Q2(R2) provide complementary frameworks for development and validation across the analytical lifecycle.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Define the measurement before choosing the instrument
  • Build understanding during development
  • Match validation to the intended use

Define the measurement before choosing the instrument

Begin with the quality attribute and the decision the result must support. An identity test, an assay and a trace impurity determination have different performance needs. State the analyte, matrix, reportable range and the level of uncertainty that is acceptable for the intended decision. An analytical target profile can capture these requirements without committing prematurely to a particular technology.

Q14 describes the analytical target profile and explains that its formal documentation and submission are optional. It should not be presented as a mandatory standalone document for every method. The practical benefit is the discipline of linking method capability to the measurement need. R05

Build understanding during development

Development should examine the variables likely to affect the reported result. For chromatography these may include extraction, pH, stationary phase, gradient delivery, temperature and detection. Sample preparation deserves particular attention because a precise instrument cannot correct incomplete extraction or analyte loss before injection.

Use prior knowledge and risk assessment to prioritise experiments. A multifactor study can be useful where interactions are likely, while a simpler investigation may adequately resolve a narrow question. Q14 accommodates different development approaches; it does not require every procedure to use design of experiments or to establish a formal design space.

Match validation to the intended use

Q2(R2) relates performance characteristics to the type of analytical measurement. The validation plan should justify the selected studies, their design and their acceptance criteria. A quantitative impurity method operating near its lower range needs different evidence from a principal-component assay. The plan should reflect how routine reportable results will actually be generated. R04

Avoid treating a familiar correlation coefficient or precision threshold as a universal regulatory requirement. A high correlation coefficient can coexist with meaningful bias at the bottom of a calibration range. Accuracy and precision must be examined at concentrations relevant to the decision, with suitable consideration of matrix and preparation effects.

Separate related concepts

Repeatability measures variation under closely controlled conditions. Intermediate precision explores within-laboratory changes such as analysts, days or equipment. Robustness examines the effect of deliberate changes to procedure parameters. These studies answer different questions and should not be treated as interchangeable labels for repeated injections.

Similarly, the reporting range and instrument working range need to be connected through the actual dilution scheme. If a procedure claims a low reporting limit but sample preparation introduces a large dilution, the instrument must still provide reliable performance at the resulting solution concentration. The illustration illustrates how the intended measurement connects to development, validation and routine monitoring.

Explore the scienceAnalytical Lifecycle

An analytical lifecycle

Measurementpurpose
Measurement need

Define the analyte, matrix, reportable range and decision before selecting a technique.

Conceptual illustration. Select a topic to explore its role. The visual does not establish formulation performance or prescribe universal regulatory requirements.

Measurement needs inform development and validation; routine observations feed subsequent changes. This is an original explanatory synthesis of analytical lifecycle principles.

Design controls that protect the result

System suitability should detect failures relevant to the procedure, such as inadequate separation of a critical pair. It cannot demonstrate that every sample was weighed, extracted or diluted correctly. Add appropriate preparation controls, solution-stability limits and reference-standard management where their contribution is important.

Consider a hypothetical impurity method with an intended reporting threshold of 0.05%. A convincing development package would show that a 0.05% spike can be recovered and measured in the product matrix, that relevant interferents are controlled and that low-level performance persists across routine operating conditions. The numerical threshold is illustrative, not a standard applicable to all impurities.

Maintain the procedure after validation

Once a procedure is in use, review relevant performance indicators. Recurring integration difficulties, unstable standards or rising invalid-run rates may reveal an emerging problem even when final results remain acceptable. Evaluate changes through the quality system and determine the extent of additional development, validation or transfer work needed.

Stabicon can support a connected development and validation programme in which protocols, experimental evidence and operating controls explain why a procedure is fit for its intended purpose. This gives receiving laboratories and regulatory reviewers a clearer basis for assessing the method.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R04
    ICH Q2 R2 Validation of Analytical Procedures

    Final guideline adopted November 2023. Analytical validation framework.

  2. R05
    ICH Q14 Analytical Procedure Development

    Final guideline adopted November 2023. Development and lifecycle approaches.

  3. R06
    ICH Q10 Pharmaceutical Quality System

    Final guideline, 2008. Pharmaceutical quality system and lifecycle management.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin